Clinical trial

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

COMPASS PathwaysActive, not recruitingPhase 3Started Feb 14, 2023572 enrolledUnited States, Canada, Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden, United KingdomNCT05711940

Abstract

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

Treatment Resistant Depression

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Shah K, Trivedi C, Kamrai D +2

Europe PMC2022

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023

ArticlePsilocybin

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways.

Yao S, Wei C, Lin H +5

Europe PMC2022